Rongchang, Lepu, and Kelun are enthusiastic about research and development.

Lepu Bio: Lepu Bio’s R&D pipeline includes a variety of ADC products, of which MRG003 is the first and only ADC drug targeting EGFR currently in the clinical research stage, which is made up of EGFR-targeting monoclonal antibodies and MMAE linked through vc
.
MRG003 is currently conducting phase II clinical trials in China for single-drug use in recurrent or metastatic advanced HNSCC (head and neck squamous cell carcinoma), NSCLC, BTC and NPC (nasopharyngeal carcinoma)
.
According to the preliminary results of the phase I clinical trial, the ORR of MRG003 for mHNSCC is 40%; the ORR for NPC is 44%, which is significantly better than the treatment plan of cetuximab combined with carboplatin
.

Kelun Pharmaceutical: Kelun Pharmaceutical’s ADC drugs involve multiple targets such as Her2, Trop2 and Claudin 18.
2.
Among them, SKB264 is a TROP-2 ADC drug independently developed by Kelun Botai, which contains three main components: 1 ) Recombinant anti-Trop2 humanized monoclonal antibody; 2) Linker containing 2-(methylsulfonyl) pyrimidine linker; 3) Topoisomerase inhibitor KL610023
.
On April 9, 2020, Kelunbotai's SKB264 received a clinical trial notice from the State Food and Drug Administration
.
Currently, SKB264 is in Phase I/II clinical
.

Zhejiang Medicine: Zhejiang Medicine's ARX788 is a HER2-ADC drug, which is a combination of trastuzumab and AS269
.
Through precise design, ARX788 specifically connects two cytotoxin AS269 to the antibody with trastuzumab as the basic backbone
.
ARX788 uses unnatural amino acid site-specific coupling technology, which greatly improves the stability and uniformity of the product, and is currently in phase I/II clinical trials
.